Literature DB >> 12748476

CA 125 levels in the preoperative assessment of advanced-stage uterine cancer.

Helen Jhang1, Linus Chuang, Paul Visintainer, Gita Ramaswamy.   

Abstract

OBJECTIVE: The purpose of this study was too evaluate preoperative levels of CA 125 in for the prediction of advanced uterine cancer. STUDY
DESIGN: We conducted a retrospective analysis of the correlation of preoperative CA 125 with grade, depth of invasion, lymph vascular space involvement, lymph node status, and stage.
RESULTS: High CA 125 levels correlated with advanced-stage (P <.0001) and positive (P <.0001) lymph node status. High levels of CA 125 also correlated with the deepest myometrial invasion, the presence of lymph vascular space involvement, and the highest grade. Receiver-operator characteristic curves demonstrated that depth of invasion, lymph vascular space involvement, and grade accurately predicted advanced-stage disease 73%, 77% and 80% of the time, respectively. CA 125 levels, however, correctly predicted advanced stage 94% of the time. The sensitivity and specificity of a CA 125 cutoff level of 37 IU/mL were 95% and 90%, respectively, with a positive predictive value of 78% and a negative predictive value of 97%.
CONCLUSION: CA 125 appears to be a significant independent predictor of positive lymph node status and the extrauterine spread of disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748476     DOI: 10.1067/mob.2003.304

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

2.  The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer.

Authors:  Marina Frimer; June Y Hou; Thomas C McAndrew; Gary L Goldberg; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2012-09-20       Impact factor: 3.060

3.  The role of CA125 in clinical practice.

Authors:  E L Moss; J Hollingworth; T M Reynolds
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

4.  Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Authors:  Richard G Moore; Amy K Brown; M Craig Miller; Donna Badgwell; Zhen Lu; W Jeffrey Allard; C O Granai; Robert C Bast; Karen Lu
Journal:  Gynecol Oncol       Date:  2008-05-21       Impact factor: 5.482

5.  Utility of Preoperative CA125 Assay in the Management Planning of Women Diagnosed with Uterine Cancer.

Authors:  N Povolotskaya; N Das; K Dhar; D Brinkmann; F Gardner; R Woolas
Journal:  Surg Res Pract       Date:  2014-02-27

Review 6.  Surgical management of early endometrial cancer: an update and proposal of a therapeutic algorithm.

Authors:  Francesca Falcone; Giancarlo Balbi; Luca Di Martino; Flavio Grauso; Maria Elena Salzillo; Enrico Michelino Messalli
Journal:  Med Sci Monit       Date:  2014-07-26

7.  Efficacy of endocervical curettage and CA-125 measurement in endometrial serous carcinoma: A case series and literature review.

Authors:  Ahmet Cem İyibozkurt; Murat Doğan; Ercan Baştu; Hamdullah Sözen; Doğan Vatansever; Samet Topuz; Sinan Berkman
Journal:  Turk J Obstet Gynecol       Date:  2015-09-15

8.  Cancer antigen 125 is associated with disease status in uterine carcinosarcoma.

Authors:  Malcolm Strachan Ross; Chelsea Kilpatrick Chandler; Koji Matsuo; John Austin Vargo; Esther Elishaev; Nalyn Siripong; Jessica Layne Berger; Joseph Leo Kelley; Sarah Elizabeth Taylor
Journal:  Rare Tumors       Date:  2019-11-07

Review 9.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

10.  Promoter-level transcriptome in primary lesions of endometrial cancer identified biomarkers associated with lymph node metastasis.

Authors:  Emiko Yoshida; Yasuhisa Terao; Noriko Hayashi; Kaoru Mogushi; Atsushi Arakawa; Yuji Tanaka; Yosuke Ito; Hiroko Ohmiya; Yoshihide Hayashizaki; Satoru Takeda; Masayoshi Itoh; Hideya Kawaji
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.